Composition, form of production and packaging
Solution for intravenous and / m introduction 1 ml
serotonin adipate 10 mg
1 ml - ampoules (5) - packings of cellular contour (1) - packs cardboard.
5 ml - ampoules (1) - packings of cellular contour (1) - packs cardboard.
5 ml - ampoules (5) - packings of cellular contour (1) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2014.
Hemostatic and serotonergic. The haemostatic effect of Dynaton is due to its ability to increase platelet aggregation and capillary resistance, as well as a reduction in bleeding time. Serotonin causes narrowing of the vessels of the kidneys and has an antidiuretic effect. It binds to serotonin receptors of smooth muscles of internal organs and normalizes its contractile activity (endogenous vasomotorics, peristalsis). The manifestation of the normalization of smooth muscle function is the stabilization of hemodynamics, the restoration of motor-evacuation function of the gastrointestinal tract, the reduction of local hypoxia.
In blood plasma quickly deaminated and loses its activity. Has no cumulative effect.
- functional intestinal obstruction (PKN);
- hemorrhagic syndrome: with Verlhof disease, against the background of treatment with cytostatics, with acute, subacute and chronic radiation sickness, with malignant neoplasms;
- hypo-and aplastic anemia;
- hemorrhagic vasculitis.
For the prevention and treatment of obstruction (PKN): intravenously into the central vein at a rate of 5-10 mg / h, previously dissolving the contents of the ampoule (10 mg) in 100-200 ml of physiological solution. When administered to the peripheral vein, 10-20 mg should be dissolved in 200-400 ml of saline. The maximum daily dose can reach 360 mg and above.
Intravenous: 20-50 mg are diluted in 200-400 ml of 0.9% sodium chloride solution; injected dropwise (30 cap / min) 2-3 times a day before the appearance or strengthening of a weakened peristalsis and clinical manifestations of recovery of motor-evacuation function of the gastrointestinal tract.
For the prevention and treatment of hemorrhagic syndrome associated with Verlhof disease, treatment with cytostatics, radiation sickness, malignant neoplasms, hypo- and aplastic anemia, thrombocytopenia. hemorrhagic vasculitis begins with intravenous administration, then goes on to intramuscular injections. The initial dose is 5 mg; in the absence of side effects, the dose is increased to 10 mg, not more than 15-20 mg / day. The course of treatment - an average of 10 days.
Intravenous: 5-10 mg of the drug is diluted in 100-150 ml of a 0.9% solution of sodium chloride or in 5-10 ml of 0.9% sodium chloride solution, followed by dilution in 100-150 ml of 5% dextrose solution (plasma, canned blood) and injected drip (no more than 30 cap / min) no more than 2 times a day.
Intramuscularly: 5-10 mg is diluted in 5 ml of a 0.5% solution of lidocaine; Enter 2 times a day at intervals of not less than 4 hours.
From the urinary system: a decrease in diuresis.
From the digestive system: abdominal pain, nausea, diarrhea.
From the respiratory system: difficulty breathing.
From the cardiovascular system: cardialgia, increased blood pressure.
Other: pain along the vein (with rapid administration), with intramuscular injection - soreness at the injection site, a feeling of heaviness in the occipital region.
If any of the side effects indicated in the manual are aggravated or you notice any other side effects not listed in the instructions, inform your doctor.
Precautions for use
In case of side effects, it is necessary to suspend the drug for 2-3 minutes and continue again at a slower rate.
- hypersensitivity to any component of the drug;
glomerulonephritis (acute and chronic);
- kidney disease;
- oligo- and anuria;
- arterial hypertension;
- Acute thrombosis;
- bronchial asthma;
- diseases accompanied by hypercoagulability.
PREGNANCY AND LACTATION
In pregnancy, the effect of the drug has not been studied, since the drug is rapidly deaminated in the bloodstream.
Breastfeeding is not a contraindication for its use.
APPLICATION FOR FUNCTIONS OF THE LIVER
The drug is contraindicated in patients with kidney disease.
The effect of the drug on the ability to drive vehicles, mechanisms
Information about the adverse impact of Dynaton on the ability to manage vehicles and mechanisms are absent.
Symptoms: hyperemia of the skin, tachypnea.
Treatment: no specific treatment is required. It is necessary to suspend the administration of the drug for 5-10 minutes and continue again at a slower rate.
Serotonin potentiates the effect of narcotic, hypnotic and analgesic drugs. It is not recommended to co-administer with calcium chloride preparations.
In the event that you are taking other medicines, be sure to consult a doctor before taking the drug.
TERMS OF RELEASE FROM PHARMACY
The drug is released by prescription.
TERMS AND CONDITIONS OF STORAGE
In a dry, protected from light place at a temperature of no higher than 25 В° C. Keep out of the reach of children. Shelf life - 3 years.